Literature DB >> 6678871

Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group.

W A Knight, C Fabian, J J Costanzi, S E Jones, C A Coltman.   

Abstract

The Southwest Oncology Group has evaluated methyl-GAG on a weekly schedule among patients with lymphoma and Hodgkin's disease. Among 56 fully and partially evaluable patients responses were seen in 3 of 10 patients with Hodgkin's disease and 11 of 46 patients with lymphoma. Toxicity was acceptable. Methyl-GAG has significant antitumor activity among this group of heavily pretreated patients. Additional trials of methyl-GAG in combination with other agents are underway.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6678871     DOI： 10.1007/bf00208895

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

1.  Phase I-II trial of methyl-GAG in advanced colon cancer. a Southwest Oncology Group pilot study.

Authors:  J W Myers; W A Knight; R B Livingston; C Fabian; J Costanzi
Journal:  Cancer Clin Trials       Date:  1981

2.  Methyl-GAG in advanced colon cancer: a phase II trial of the Southwest Oncology Group.

Authors:  W A Knight; D M Loesch; L P Leichman; C Fabian; R M O'Bryan
Journal:  Cancer Treat Rep       Date:  1982-12

Review 3.  Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects.

Authors:  R P Warrell; J H Burchenal
Journal:  J Clin Oncol       Date:  1983-01       Impact factor: 44.544

4.  Phase I-II trial of methyl-GAG: a Southwest Oncology Group Pilot Study.

Authors:  W A Knight; R B Livingston; C Fabian; J Costanzi
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

5.  Effectiveness of methyl-GAG (methylglyoxal-bis[guanylhydrazone]) in patients with advanced malignant lymphoma.

Authors:  R P Warrell; B J Lee; S J Kempin; M J Lacher; D J Straus; C W Young
Journal:  Blood       Date:  1981-06       Impact factor: 22.113
  5 in total
  3 in total

1.  Cisplatin, VP-16-213 and MGBG (methylglyoxal bis guanylhydrazone) combination chemotherapy in refractory lymphoma, a phase II study.

Authors:  L Dabich; M K Liepman
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

2.  Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG).

Authors:  J A Gastaut; G Tell; P J Schechter; D Maraninchi; B Mascret; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Development and Validation of HPLC-DAD and UHPLC-DAD Methods for the Simultaneous Determination of Guanylhydrazone Derivatives Employing a Factorial Design.

Authors:  Wanessa Azevedo de Brito; Monique Gomes Dantas; Fernando Henrique Andrade Nogueira; Edeildo Ferreira da Silva-Júnior; João Xavier de Araújo-Júnior; Thiago Mendonça de Aquino; Êurica Adélia Nogueira Ribeiro; Lilian Grace da Silva Solon; Cícero Flávio Soares Aragão; Ana Paula Barreto Gomes
Journal:  Molecules       Date:  2017-08-30       Impact factor: 4.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.